All Oncology News

Luciano J. Costa, MD, PhD, shares key updates regarding transplanteligible and -ineligible patients with multiple myeloma, novel triplet and quadruplet regimens that are shifting standards in the frontline setting, and other modalities under active exploration.

In the United States, a geographic mismatch exists between the number of medical oncology and radiation providers and patients needing care, with more specialists clustered in urban and metropolitan areas.

Findings from the pivotal phase 3 PACIFIC and ADAURA trials have not only led to paradigm shifts and served as the basis for ongoing research for patients with unresectable and resectable non–small cell lung cancer, respectively, but have emphasized the importance of distinguishing treatment options based on the presence or absence of an oncogenic driver.

Although fewer deaths were reported with neratinib in patients with HER2-positive breast cancer treated on the phase 3 ExteNET trial, the agent was not found to result in a significant improvement in overall survival after 8 years of follow-up.

Nina Shah, MD, discusses the newfound role of BCMA-directed CAR T-cell therapies in multiple myeloma, how the field may select between ide-cel and cilta-cel if the latter is approved, and novel cellular therapies in clinical development.

Stratification by the molecular 70-gene risk prediction signature revealed that patients with estrogen receptor–positive breast cancer who are low risk for disease recurrence derive greater benefit from tamoxifen, while those who are high risk have greater benefit from goserelin vs no endocrine therapy.

Frequently dysregulated in cancer cells, the PI3K pathway has long been a high-priority therapeutic target in oncology. However, initial efforts with pan–class I PI3K inhibitors were hampered by disappointing efficacy and substantial toxicity.

Nagashree Seetharamu, MD, MBBS, discusses emerging targets in non–small cell lung cancer and the limitations of current biomarkers.

Conflicting results from the phase 3 monarchE, PENELOPE-B, and PALLAS trials have thrown the role of adjuvant CDK4/6 inhibition into question in patients with high-risk, early-stage hormone receptor–positive, HER2-negative breast cancer.

Daniel J. George, MD, discussed how tivozanib differs from other TKIs and its potential to fill an unmet need in the treatment of patients with renal cell carcinoma.

Neil Morganstein, MD, discusses the impact of lurbinectedin on the SCLC treatment paradigm and future research directions with the agent in this population.

Edward S. Kim, MD, highlights efforts being made to overcome resistance to EGFR TKIs in patients with EGFR-mutated NSCLC and factors to consider when determining sequential treatment.

Effective early detection and optimal management are critical in preventing high-grade interstitial lung disease, a treatment-related adverse effect of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive metastatic breast cancer.

Distinct gene signatures, with the exception of estrogen receptor signaling and BRCAness, are associated with pathologic complete response and invasive disease-free survival, in patients with HER2-positive breast cancer who received trastuzumab and pertuzumab alone or in combination with paclitaxel.

The differentiated TROP2-directed antibody-drug conjugate datopotamab deruxtecan was found to have promising antitumor activity with a manageable safety profile in heavily pretreated patients with triple-negative breast cancer.

Approximately 30% of breast cancer tumors can covert from, or to, HER2-low status, underscoring the need to retest for HER2 expression upon relapse.

Thomas Bachelot, MD, discussed how to approach treatment of patients with HER2-positive breast cancer and CNS metastases and the impact of tucatinib in this population.

Although administering trastuzumab for 1 year in patients with HER2-positive early breast cancer continues to be standard, a 9-week de-escalation approach may be a reasonable option in a large proportion of the real-world HER2-positive population.

Ribociclib plus endocrine therapy improved overall survival and post-progression outcomes in pre- or postmenopausal patients with hormone receptor–positive, HER2-negative advanced breast cancer irrespective of age.

Treatment with atezolizumab plus carboplatin demonstrated early clinical activity in patients with metastatic invasive lobular breast cancer, with slight trends toward increased clinical benefit in patients with triple-negative ILC and responders with higher PD-L1 expression, according to initial findings of the non-randomized phase 2 GELATO trial.

Daratumumab plus lenalidomide and dexamethasone, or plus bortezomib and dexamethasone each led to higher rates of minimal residual disease negativity compared with lenalidomide plus dexamethasone or bortezomib plus dexamethasone alone in patients with relapsed/refractory multiple myeloma who were enrolled in the phase 3 POLLUX and CASTOR trials, translating to prolonged, durable remissions.

During this search for a breast cancer support system, my mother also investigated complementary therapies that peers had used to help cope with their fears, adverse effects, and feelings of helplessness.

The combination of durvalumab plus tremelimumab and platinum-based chemotherapy resulted in a significant improvement in overall survival compared with chemotherapy alone in the frontline treatment of patients with stage IV non–small cell lung cancer.

Post-treatment care for breast cancer survivors must be personalized to address each survivor’s unique experiences.

Erminia Massarelli, MD, MS, PhD, shares key updates in immunotherapy and targeted treatment for patients with NSCLC

Although the standard-of-care treatment for patients with metastatic pancreatic cancer remains largely unchanged with multi-agent chemotherapy, the role for multidisciplinary care has expanded significantly in recent years.

Ravi Salgia, MD, PhD, discusses pivotal trials that have shaken up the SCLC treatment paradigm and novel immunotherapy regimens under investigation.

The recently FDA-approved loncastuximab tesirine-lpyl has been added to the latest National Comprehensive Cancer Network Clinical Practice Guidelines for B-cell lymphomas.

Arsen Osipov, MD, discusses the potential for ongoing research with immunotherapeutic approaches in gastrointestinal malignancies, including CAR T-cell therapy, bispecific T-cell engagers, and vaccines.

Olwen Hahn, MD, discusses the clinical significance of the KATHERINE and FeDeriCa trials in the treatment of patients with early-stage HER2-postive breast cancer.